MOTS-c: The Mitochondrial-Derived Peptide and Its Role in Metabolic Research

MOTS-c (Mitochondrial Open reading frame of the twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — making it one of a small class of bioactive peptides translated from mitochondrial DNA rather than nuclear DNA. First characterised by Lee et al. at the University of Southern California in 2015, it has since accumulated a growing preclinical research record focused on metabolic regulation, skeletal muscle glucose uptake, and exercise-associated signalling pathways.

Origin: mitochondrial DNA encoding

The standard view of mitochondrial DNA (mtDNA) is that it encodes only 13 proteins (all components of the oxidative phosphorylation complexes), 22 tRNAs, and 2 rRNAs. MOTS-c challenged this view by demonstrating that small open reading frames within mitochondrial rRNA genes can encode bioactive peptides. MOTS-c is translated from a 51-nucleotide ORF within the 12S rRNA gene.

This origin is not merely a curiosity — it has mechanistic implications. MOTS-c is translated in the mitochondrial matrix, but can translocate to the nucleus under stress conditions, where it functions as a transcriptional co-regulator. The peptide effectively acts as a retrograde signal from the mitochondria to the nucleus, communicating cellular energy status. This is a qualitatively different signalling topology from conventional endocrine peptides, which are synthesised in the ER and secreted.

Proposed mechanisms of action

AMPK activation and glucose metabolism

The most replicated mechanistic finding is MOTS-c activation of AMP-activated protein kinase (AMPK), the central cellular energy sensor. In skeletal muscle cell models, MOTS-c treatment increases AMPK phosphorylation (Thr172), which promotes GLUT4 translocation to the plasma membrane and enhances glucose uptake independent of insulin signalling. This places MOTS-c mechanistically adjacent to metformin and exercise-induced AMPK activation, both of which improve glucose disposal through overlapping pathways.

The proposed upstream mechanism involves MOTS-c interference with the folate cycle and methionine metabolism within the mitochondria, leading to accumulation of ZMP (AICAR monophosphate), which directly activates AMPK. This two-step mechanism — metabolic cycle interference leading to AMPK activator accumulation — distinguishes MOTS-c from direct AMPK activators like AICAR.

Nuclear translocation and stress response

Under conditions of metabolic or oxidative stress, MOTS-c translocates from the mitochondrial matrix to the cytoplasm and ultimately to the nucleus. Nuclear MOTS-c has been shown to interact with Nrf2 and regulate antioxidant response element (ARE)-dependent gene expression, including upregulation of SOD2, catalase, and other mitochondrial stress-response genes. This positions MOTS-c as a retrograde mitochondrial stress signal with a direct nuclear gene expression function.

Exercise-associated signalling

A notable 2019 study by Reynolds et al. (Cell Metabolism) demonstrated that plasma MOTS-c levels increase significantly during and after acute exercise in humans. The study also showed that exogenous MOTS-c administration in aged mice improved exercise capacity to levels comparable to young controls. The proposed mechanism involves MOTS-c-mediated AMPK activation in skeletal muscle, improving metabolic flexibility and oxidative capacity during exercise stress.

Insulin sensitivity

Multiple rodent studies have demonstrated improved insulin sensitivity with MOTS-c administration in diet-induced obesity and high-fat-diet models. The mechanistic basis proposed is the combination of enhanced skeletal muscle glucose uptake (via GLUT4 translocation) and reduced hepatic gluconeogenesis (via AMPK-mediated suppression of PEPCK and G6Pase expression).

The ageing connection

Circulating MOTS-c levels have been reported to decline with age in both rodent and human studies. The University of Southern California group and others have proposed MOTS-c as a mitochondrial-derived mediator of exercise-associated benefits whose decline may contribute to the metabolic deterioration seen in ageing muscle. This framing has driven substantial research interest but also significant popular media coverage that outpaces the current evidence base.

It is important to be precise here: the current human evidence is observational (circulating level changes) and the mechanistic evidence is primarily from cell culture and rodent models. The translation to human physiology at equivalent circulating concentrations is not established by RCT data.

Current evidence limitations

The MOTS-c literature is expanding but still primarily preclinical. Key gaps include:

• No published Phase 2 or 3 randomised controlled trials in humans
• Pharmacokinetic data in humans is limited; the circulating half-life after exogenous administration is not well characterised
• Optimal concentration ranges for in vitro studies vary significantly across published protocols, making inter-laboratory comparison difficult
• The nuclear translocation mechanism has been characterised in cell models but the conditions required for this translocation in vivo remain unclear

Structural and handling notes

MOTS-c is a 16-amino-acid peptide (sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) with a molecular weight of approximately 2174 Da. It is soluble in sterile water and does not require acidic co-solvents. The methionine residues at positions 1 and 6 are susceptible to oxidation; mass spectrometry confirmation on the COA should verify the unoxidised form (+16 Da on Met indicates oxidation and is a quality red flag). See our COA reading guide for the mass spec verification step.

Australian regulatory status

MOTS-c is a Schedule 4 substance under the TGA Poisons Standard. It is not listed on the ARTG and is available for in vitro laboratory and educational research only. See our Australian regulatory guide for the full RUO framework. Browse all research compounds in our catalogue.

Key references

• Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
• Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
• Kim SJ et al. Mitochondrially derived peptides as novel regulators of metabolism. J Physiol. 2017;595(21):6613-6621.
• Zarse K, Ristow M. A mitochondrially encoded hormone ameliorates obesity and insulin resistance. Cell Metab. 2015;21(3):355-356.

For context on how mitochondrial-linked metabolic peptides compare structurally with incretin-class compounds, see our overview of peptide classes.